血浆可溶性二肽基肽酶-4与缺血性卒中后主要心血管事件风险:中国急性缺血性卒中抗高血压试验(CATIS)的二次分析
该研究基于CATIS试验中3564例急性缺血性卒中患者(男2270例、女1294例),分析基线血浆sDPP4水平与2年临床结局的关联。最高sDPP4四分位组较低四分位组的心血管事件、复发性卒中、全因死亡、卒中特异性死亡及不良功能结局风险均降低,且加入sDPP4可改善风险预测。
要点
- 最高sDPP4四分位组较低四分位组2年心血管事件风险降低(HR 0.62,95%CI 0.45-0.87)。
- 最高sDPP4四分位组复发性卒中风险降低(HR 0.70,95%CI 0.49-0.99)。
- 最高sDPP4四分位组全因死亡和卒中特异性死亡风险均降低。
核心结论
- 急性缺血性卒中患者血浆sDPP4水平较高与心血管事件、复发性卒中、全因死亡及不良功能结局风险降低相关。
研究设计与样本
- 研究为对中国急性缺血性卒中抗高血压试验(CATIS)的二次分析,共纳入3564例参与者(男2270例、女1294例),均有基线血浆sDPP4水平测量。
- 研究采用logistic回归和Cox回归模型评估血浆sDPP4水平与2年临床结局的关联,并通过计算净重分类指数和综合判别改善指数探讨sDPP4的预测效用。
主要发现
- 在多变量模型中,与最低sDPP4类别相比,最高血浆sDPP4四分位组2年心血管事件风险降低(HR 0.62,95%CI 0.45-0.87)。
- 最高sDPP4四分位组2年复发性卒中风险降低(HR 0.70,95%CI 0.49-0.99)。
- 最高sDPP4四分位组2年全因死亡风险降低(HR 0.62,95%CI 0.44-0.87),卒中特异性死亡风险降低(HR 0.65,95%CI 0.44-0.94)。
- 最高sDPP4四分位组2年不良功能结局风险降低(OR 0.66,95%CI 0.53-0.82)。
- 将血浆sDPP4加入常规危险因素模型后,显著改善了所有结局的风险预测。
临床怎么用
- 作者认为,血浆sDPP4可能作为急性缺血性卒中患者初始风险分层的潜在预后标志物。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Recent studies have suggested that plasma soluble dipeptidyl peptidase-4 (sDPP4) have important physiologic effects, which may influence the prognosis of ischemic stroke. Our study aimed to examine the relationship between plasma sDDP4 levels and long-term clinical outcomes among patients with acute ischemic stroke. METHODS: Secondary analysis was conducted among 3,564 participants (2,270 men and 1,294 women) from the China Antihypertensive Trial in Acute Ischemic Stroke with baseline measurement of plasma sDPP4 levels. We evaluated the associations between plasma sDPP4 levels and 2-year clinical outcomes using logistic regression and Cox regression models. We further investigated the predictive utility of sDPP4 by calculating net reclassification index and integrated discrimination improvement. RESULTS: The highest plasma sDPP4 quartile was associated with lower risk of cardiovascular events (hazard ratio [HR] 0.62, 95% confidence interval [CI] 0.45-0.87), recurrent stroke (HR 0.70, 95% CI 0.49-0.99), all-cause mortality (HR 0.62, 95% CI 0.44-0.87), stroke-specific mortality (HR 0.65, 95% CI 0.44-0.94), and poor functional outcomes (odds ratio 0.66, 95% CI 0.53-0.82) at 2 years compared with the lowest sDPP4 category in multivariable models. The addition of plasma sDPP4 to conventional risk factors model significantly improved risk prediction of all outcomes. DISCUSSION: In this study, we found that higher plasma sDPP4 levels in patients with acute ischemic stroke were associated with decreased risks of cardiovascular events, recurrent stroke, all-cause mortality, and poor functional outcomes after ischemic stroke. These findings suggest that plasma sDPP4 may be a potential prognostic marker for initial risk stratification in patients with acute ischemic stroke.
引用
- You S, Miao M, Lu Z, et al. Plasma Soluble Dipeptidyl Peptidase-4 and Risk of Major Cardiovascular Events After Ischemic Stroke: Secondary Analysis of China Antihypertensive Trial in Acute Ischemic Stroke (CATIS). Neurology. 2022. PMID: 35654589. doi:10.1212/WNL.0000000000200784
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。